ContributorsPublishersAdvertisers

Fredrik Schjesvold, MD, PhD, Discusses the Implications of an FDA Approval for Melflufen in Transplant-Naïve Relapsed/Refractory Multiple Myeloma

cancernetwork.com
 2021-10-03

Cover picture for the articleCancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how he would like to see the OCEAN trial and Melflufen progress for relapsed/refractory multiple myeloma. At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Fredrik Schjesvold, MD, PhD, founder and head...

www.cancernetwork.com

Comments / 0

Comments / 0